Temple Health has partnered with ThinkSono, a UK-based artificial intelligence company, to research a new generation of synthetic intelligence (AI)-based ultrasound that enables faster and more portable diagnosis of deep vein thrombosis (DVT).
LONDON, ENGLAND / ACCESSWIRE / February 13, 2024 / Temple Health is partnering with ThinkSono, a UK-based AI company, to study a new artificial intelligence (AI)-powered ultrasound technology that enables more rapid and portable diagnosis of deep vein thrombosis (DVT).
DVT, a condition in which blood clots expand in the veins, can cause life-threatening headaches, such as the spread of blood clots to the center and lungs (called a pulmonary embolism), as well as debilitating swelling and pain in the veins. long-term in the legs (called post-thrombotic syndrome). According to the U. S. Centers for Disease Control and Prevention,In the U. S. , DVT affects up to 900,000 Americans a year and is not unusual among hospitalized patients. DVT is also a major driving force in physical care costs, costing the U. S. physical care formula up to $10 billion a year.
Early diagnosis of blood clots is incredibly important. The ThinkSono generation leverages real-time, AI-based point-of-care ultrasound to potentially detect DVT faster, more accurately, and more cost-effectively than classic methods.
“There is an important need for immediate and effective diagnostic tools, as DVT can go unnoticed or misdiagnosed,” said Parth Rali, MD, associate professor of medicine and thoracic surgery at Temple University’s Lewis Katz School of Medicine and Temple’s principal investigator for the lawsuit. “Temple’s Pulmonary Embolism Response Team (PERT) has extensive experience diagnosing and treating those harmful blood clots and we are excited to add this new tool to our arsenal.
Researchers will perform classic ultrasound scans on patients with and without DVT, as well as analysis of the ThinkSono steering system. The realization of the two strategies will be to compare and validate the accuracy of the ThinkSono system.
Temple joins NYU Langone Health as the second US-based site of the trial. The research team – including internal medicine resident Ka U Lio, MD, and Christie DiVeterano, NP – hopes to conclude the study and publish the results in the coming year, in preparation for subsequent FDA submission.
“Given that 100,000 Americans die of blood clots each year, we are pleased that Temple University Hospital will be one of the sites participating in the ThinkSono study to detect blood clots faster,” said Gary S. Cohen, MD, FSIR, Herbert M. Stauffer Chair of Diagnostic Imaging at Lewis Katz School of Medicine at Temple University, and an interventional radiologist involved in the trial.
Fouad Al Noor, CEO of ThinkSono, said, “We are incredibly pleased that ThinkSono is working with Temple Health, one of the leading institutions in the United States, with a specific focus on DVT. The prospect of AI-based generation for ultrasound guidance and DVT detection is immense and will definitely improve patient management. We are thrilled that Temple Health is helping to make this vision a reality. “
About Temple HealthTemple University Health System (Temple Health) is a $2. 6 billion school fitness formula committed to providing access to quality patient care and supporting excellence in medical education and research. You can get more data here.
Coordinates
Fouad Noor, Executive Director hello@thinksono. com
SOURCE: ThinkSono Ltd
View the original press release on newswire.com.